Scholarlink

Background <p>Colorectal peritoneal metastases (CRPM) represent a significant treatment challenge for patients with colorectal cancer that significantly impact quality of life and limit survival.</p> Patients and Methods <p>Systemic chemotherapy represents the current mainstay of management for metastatic disease, but the use of cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is being established as a promising option with survival benefit for select patients.</p> Results <p>Identifying best management practices for patients with CRPM is critical as intervention with CRS/HIPEC can carry significant risks of morbidity and mortality.</p> Conclusions <p>This guideline report aims to summarize the existing literature regarding optimal management of patients with CRPM and current areas of ongoing investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Michael M. Wach,
  • Sean P. Dineen

摘要

Background

Colorectal peritoneal metastases (CRPM) represent a significant treatment challenge for patients with colorectal cancer that significantly impact quality of life and limit survival.

Patients and Methods

Systemic chemotherapy represents the current mainstay of management for metastatic disease, but the use of cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is being established as a promising option with survival benefit for select patients.

Results

Identifying best management practices for patients with CRPM is critical as intervention with CRS/HIPEC can carry significant risks of morbidity and mortality.

Conclusions

This guideline report aims to summarize the existing literature regarding optimal management of patients with CRPM and current areas of ongoing investigation.